A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol.
Jacek HajdaMonika LehmannOttheinz KrebsMeinhard KieserKarsten GeletnekyDirk JägerMichael DahmBernard HuberTilman SchöningOliver SedlaczekAlbrecht StenzingerNiels HalamaVolker DanielBarbara LeuchsAssia AngelovaJean RommelaereChristine E EngelandChristoph SpringfeldGuy UngerechtsPublished in: BMC cancer (2017)
ClinicalTrials.gov-ID: NCT02653313 , Registration date: Dec. 4th, 2015.